T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.76B |
| 2 |
Cigna
CI
|
+$1.44B |
| 3 |
Bristol-Myers Squibb
BMY
|
+$1.26B |
| 4 |
Occidental Petroleum
OXY
|
+$763M |
| 5 |
Danaher
DHR
|
+$762M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PCYC
PHARMACYCLICS INC
PCYC
|
+$2.46B |
| 2 |
Wynn Resorts
WYNN
|
+$1.11B |
| 3 |
Netflix
NFLX
|
+$1.03B |
| 4 |
PCP
PRECISION CASTPARTS CORP
PCP
|
+$975M |
| 5 |
TWTR
Twitter, Inc.
TWTR
|
+$909M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.87% |
| 2 | Financials | 13.64% |
| 3 | Consumer Discretionary | 13.54% |
| 4 | Industrials | 10.67% |
| 5 | Technology | 10.39% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
EA
401
DELISTED
Electronic Arts
EA
| $237M | 0.05% |
3,567,512
-16,437
| -0.5% | -$1.01M |
|
|
IMS
402
DELISTED
IMS HEALTH HLDGS INC COM STK (DE)
IMS
| $237M | 0.05% |
7,734,440
+4,875,400
| +171% | +$141M |
|
403
Acadia Pharmaceuticals
ACAD
$4.89B
| $236M | 0.05% |
5,632,514
-424,909
| -7% | -$16.4M |
|
404
Cintas
CTAS
$80.3B
| $235M | 0.05% |
11,122,344
-6,240
| -0.1% | -$131K |
|
405
Regency Centers
REG
$14.1B
| $234M | 0.05% |
3,970,158
+173,103
| +5% | +$11.1M |
|
406
ASML
ASML
$710B
| $233M | 0.05% |
2,234,848
-2,412,723
| -52% | -$258M |
|
407
Monro
MNRO
$352M
| $232M | 0.05% |
3,730,500
-216,380
| -5% | -$13.5M |
|
408
Lumen
LUMN
$6.61B
| $232M | 0.05% |
7,880,365
+87,470
| +1% | +$2.98M |
|
409
White Mountains Insurance
WTM
$5.1B
| $231M | 0.05% |
352,161
+19,440
| +6% | +$12.9M |
|
410
Under Armour
UAA
$2.3B
| $231M | 0.05% |
5,527,656
-1,957,460
| -26% | -$79.2M |
|
|
THOR
411
DELISTED
THORATEC CORPORATION
THOR
| $229M | 0.05% |
5,136,729
-226,450
| -4% | -$9.91M |
|
412
Murphy Oil
MUR
$4.99B
| $229M | 0.05% |
5,501,250
-5,362,100
| -49% | -$244M |
|
|
SEM
413
DELISTED
Select Medical
SEM
| $228M | 0.05% |
26,138,072
+46,363
| +0.2% | +$389K |
|
414
Lazard
LAZ
$4.43B
| $226M | 0.05% |
4,019,620
-961,390
| -19% | -$53.5M |
|
415
Landstar System
LSTR
$6.4B
| $226M | 0.05% |
3,373,840
-299,669
| -8% | -$19.5M |
|
416
Acadia Healthcare
ACHC
$2.82B
| $225M | 0.05% |
2,873,183
+16,200
| +0.6% | +$1.17M |
|
|
SCHW
417
Charles Schwab
SCHW
$190B
| $225M | 0.05% |
6,881,867
+19,925
| +0.3% | +$630K |
|
418
WEX
WEX
$6.79B
| $223M | 0.05% |
1,959,609
+444,460
| +29% | +$50.5M |
|
419
Douglas Emmett
DEI
$1.99B
| $222M | 0.05% |
8,241,952
+888,212
| +12% | +$25.7M |
|
420
Quest Diagnostics
DGX
$26.1B
| $221M | 0.05% |
3,052,766
-2,599,650
| -46% | -$192M |
|
421
Novavax
NVAX
$1.34B
| $221M | 0.05% |
993,323
-54
| -0% | -$9.49K |
|
422
Nordson
NDSN
$17.3B
| $220M | 0.05% |
2,829,660
-140,960
| -5% | -$11.4M |
|
|
AVP
423
DELISTED
Avon Products, Inc.
AVP
| $219M | 0.05% |
35,053,209
+1,614,040
| +5% | +$12M |
|
424
Acadia Realty Trust
AKR
$2.86B
| $216M | 0.04% |
7,430,269
+184,820
| +3% | +$5.83M |
|
425
Broadcom
AVGO
$1.99T
| $216M | 0.04% |
16,259,400
+136,700
| +0.8% | +$1.79M |
|
Similar funds
T. Rowe Price Associates's Q2 2015 Portfolio in Review
As of Q2 2015, T. Rowe Price Associates held 2,615 positions worth $486B, up 0.44% from $484B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
T. Rowe Price Associates's Q2 2015 filing shows 76 new, 1,051 increased, 777 reduced and 79 closed positions. Its largest new stake was Allergan plc: 548,825 shares worth $570M. The largest sale was PHARMACYCLICS INC, an estimated $2.46B.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 21% a quarter earlier, followed by Financials and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2015 buy was Allergan plc: 548,825 shares worth $570M.
- T. Rowe Price Associates added most to Microsoft in Q2 2015, an estimated $3.76B increase.
- T. Rowe Price Associates's biggest Q2 2015 reduction was Wynn Resorts, cutting an estimated $1.11B.
- T. Rowe Price Associates fully exited PHARMACYCLICS INC in Q2 2015, selling an estimated $2.46B.
- T. Rowe Price Associates's ten largest holdings make up 14% of its $486B portfolio in Q2 2015.
- T. Rowe Price Associates opened 76 new positions and closed 79 in Q2 2015.
- T. Rowe Price Associates's portfolio value rose 0.44% quarter-over-quarter to $486B.
Based on T. Rowe Price Associates's 13F filing for Q2 2015, filed 14 Aug 2015.